×
About 7,813 results

ALLMedicine™ Hemophilia A Center

Research & Reviews  3,423 results

Von Willebrand disease: What does the future hold?
https://doi.org/10.1182/blood.2020008501
Blood Denis CV, Susen S et. al.

Mar 4th, 2021 - Von Willebrand disease (VWD) is characterized by its heterogeneous clinical manifestation, which complicates its diagnosis and management. The clinical management of VWD has remained essentially unchanged over the last 30 years or so, using von Wi...

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

B cell activating factor modulates the factor VIII immune response in hemophilia A.
https://doi.org/10.1172/JCI142906
The Journal of Clinical Investigation; Doshi BS, Rana J et. al.

Mar 2nd, 2021 - Inhibitors to factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help identify therapeutic targets...

Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with...
https://doi.org/10.1111/hae.14276
Haemophilia : the Official Journal of the World Federatio... Huang K, Zhen Y et. al.

Mar 1st, 2021 - Kovaltry (BAY81-8973) is an unmodified full-length factor VIII (FVIII) concentrate that enhances the pharmacokinetic (PK) profiles as compared to some other standard half-life time FVIII concentrates. However, the PK of Kovaltry in haemophiliac pa...

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concent...
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.

Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

see more →

Guidelines  15 results

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

Bayer Statement on Voluntary Recall of Two Lots of Kogenate FS Antihemophilic Factor (Recombinant) in the United States
https://www.drugs.com/fda/bayer-statement-voluntary-recall-two-lots-kogenate-fs-antihemophilic-factor-recombinant-united-14291.html

Jul 18th, 2019 - Bayer is voluntarily recalling two lots of Kogenate FS antihemophilic factor (recombinant) 2000 IU vials in the United States to the patient level. Certain vials from these two lots that were labeled as Kogenate FS actually contain the FVIII hemop...

Novo Nordisk receives US FDA approval of ESPEROCT® (turoctocog alfa pegol, N8-GP)
https://www.novonordisk.com/content/Denmark/HQ/www-novonordisk-com/en_gb/home/media/news-details.2235689.html

Feb 18th, 2019 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application for ESPEROCT® for the treatment of adults and children with haemophilia A. ESPEROCT® is the brand name for turoctocog alfa p...

NHF-McMaster Guideline on Care Models for Haemophilia Management
https://onlinelibrary.wiley.com/doi/abs/10.1111/hae.13008
Pai, M.

Jun 26th, 2016 - This guideline was developed to identify evidence?based best practices in haemophilia care delivery, and discuss the range of care providers and services that are most important to optimize outcomes for persons with haemophilia (PWH) across the Un.

International recommendations on the diagnosis and treatment of patients with acquired ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663620
Haematologica Huth-Kühne A, Baudo F et. al.

Apr 1st, 2009 - Acquired hemophilia A (AHA) is a rare bleeding disorder characterized by autoantibodies directed against circulating coagulation factor (F) VIII. Typically, patients with no prior history of a bleeding disorder present with spontaneous bleeding an...

see more →

Drugs  109 results see all →

Clinicaltrials.gov  3,705 results

Von Willebrand disease: What does the future hold?
https://doi.org/10.1182/blood.2020008501
Blood Denis CV, Susen S et. al.

Mar 4th, 2021 - Von Willebrand disease (VWD) is characterized by its heterogeneous clinical manifestation, which complicates its diagnosis and management. The clinical management of VWD has remained essentially unchanged over the last 30 years or so, using von Wi...

Hemostatic therapy as a management strategy for acquired hemophilia: what does the futu...
https://doi.org/10.1080/17474086.2021.1892483
Expert Review of Hematology; Franchini M, Schiavulli M et. al.

Mar 3rd, 2021 - Introduction: Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies that bind and inactivate factor VIII (FVIII), predisposing to a potentially life-threatening bleeding.Areas covered: The main epidemiological, clinical...

B cell activating factor modulates the factor VIII immune response in hemophilia A.
https://doi.org/10.1172/JCI142906
The Journal of Clinical Investigation; Doshi BS, Rana J et. al.

Mar 2nd, 2021 - Inhibitors to factor VIII (FVIII) remain the most challenging complication of FVIII protein replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII-specific B cell development could help identify therapeutic targets...

Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with...
https://doi.org/10.1111/hae.14276
Haemophilia : the Official Journal of the World Federatio... Huang K, Zhen Y et. al.

Mar 1st, 2021 - Kovaltry (BAY81-8973) is an unmodified full-length factor VIII (FVIII) concentrate that enhances the pharmacokinetic (PK) profiles as compared to some other standard half-life time FVIII concentrates. However, the PK of Kovaltry in haemophiliac pa...

Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concent...
https://doi.org/10.1055/s-0041-1725009
Thrombosis and Haemostasis; Takeyama M, Furukawa S et. al.

Feb 28th, 2021 - Emicizumab prophylaxis improves coagulation function in congenital hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab enhanced the coagulant potentials, ex vivo, in plasmas from patients with acquired hemophilia A...

see more →

News  561 results

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102_2

Oct 21st, 2020 - Hemophilia A is an inherited deficiency of FVIII and an X-linked recessive disorder. Hemophilia B, another recessive disorder, is characterized by a deficiency in factor IX. Hemophilia C is an autosomal recessive disorder in which patients are def...

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102_4

Oct 21st, 2020 - Figure 2. Frontal x-ray showing the damaged knees of a patient with hemophilia. A fracture (lower left) in the right tibia has healed. Hemophilia is often associated with external bleeding, but a more common symptom is internal bleeding, which usu...

Fast Five Quiz: Presentation and Diagnosis of Hemophilia A
https://reference.medscape.com/viewarticle/939102

Oct 21st, 2020 - Hemophilia is a blood disorder that is usually genetically inherited from a parent, except for rare cases in which it is acquired. Hemophilia A is the most common type of hemophilia, and it is estimated to affect more than 1.2 million males worldw...

Current practices in hemophilic patients undergoing orthopedic surgery - a systematic review
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588779/
Experimental and Therapeutic Medicine; Badulescu OV

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

FDA Declines to Approve BioMarin's Gene Therapy for Hemophilia A
https://www.staging.medscape.com/viewarticle/935960

Aug 19th, 2020 - (Reuters) - The U.S. Food and Drug Administration has declined to approve BioMarin Pharmaceutical Inc's gene therapy for hemophilia A, citing the need for two-year data on the therapy, the drugmaker said on Wednesday. The company, and Wall Street,...

see more →